Search results
Added:
11 months ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyIn the landmark FAIR-HF2 randomized clinical trial (NCT03036462)1, intravenous (IV) ferric carboxymaltose did not significantly reduce heart failure (HF) hospitalizations or cardiovascular deaths in patients with heart failure and iron deficiency, despite improving patient-reported quality of life outcomes. Results were presented at ACC.252 and concurrently published in JAMA3…
View more
Romaric Loffroy
Job title: Head, Department of Vascular and Interventional Radiology
Author
Nicholas Inston
Author
Evald Høj Christiansen
Job title: Clinical Associate Professor, Aarhus University Hospital, Denmark
Author
Christoph Varenhorst
Job title: Associate Professor and Senior Consultant Cardiologist
Author
Todd M Brown
Research Area(s) / Expertise:
Job title: Assistant Professor of Medicine
Author
Dinesh K Kalra
Job title: Assistant Professor
Author
Added:
2 months ago
Source:
Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments…
View more
Lina Badimon
Research Area(s) / Expertise:
Job title: Director
Author
João L Cavalcante
Research Area(s) / Expertise:
Job title: Director of Cardiac MRI and Structural CT Labs
Author